Abbott Laboratories stock rises 1.83% and outperforms major competitors

13 articles · Updated · MarketWatch · Apr 27

Shares closed at $92.80 on Monday, with trading volume reaching 15.2 million, surpassing the 50-day average of 11.4 million.
Abbott outperformed Johnson & Johnson, Pfizer, and Merck, whose stocks all declined during a mixed session for the S&P 500 and Dow Jones.
Despite the gain, Abbott remains 33.27% below its 52-week high of $139.06 set in June 2025.

Abbott's stock is near a 52-week low. Is now the perfect time to buy into its high-tech future?

Will Abbott's $23B cancer diagnostics bet successfully pivot the company's growth and revive its stock?

Why are Abbott insiders selling shares right after the company made its largest-ever acquisition?

Can strong CGM and cancer diagnostics growth offset the significant decline in Abbott's Nutrition business?

How will Abbott's new over-the-counter glucose monitors change personal health tracking for consumers?